Direct Costs of Cervical Cancer Management in Morocco |
Berraho, Mohamed
(Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine)
Najdi, Adil (Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine) Mathoulin-Pelissier, Simone (Inserm CIC-EC7, axe cancer. Institut de Sante publique Epidemiologie et Developpement (ISPED)) Salamon, Roger (Inserm CIC-EC7, axe cancer. Institut de Sante publique Epidemiologie et Developpement (ISPED)) Nejjari, Chakib (Laboratory of Epidemiology, Clinical Research and Community Health, Faculty of Medicine) |
1 | Lalla Salma Association against Cancer, (2009). National Cancer Plan, Volume 3: Etude des stades de diagnostique et des resultats de traitement des cancers au Maroc. |
2 | Lehtinen M, Paavonen J, Wheeler CM, et al (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13, 89-99. DOI ScienceOn |
3 | Mandelblatt JS, Lawrence WF, Gaffikin L, et al (2002). Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst, 94, 1469-83. DOI |
4 | Sanders GD, Taira AV (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9, 37-48. DOI |
5 | Ministry of health - Morocco (2011). Sante en chiffre 2011. |
6 | National Cancer Institute - France (2007). Etude et Expertises : Analyse economique des couts du cancer en France : Impact sur la qualite de vie, prevention, depistage, soins, recherche. |
7 | Panorama de la sante 2007 : Les indicateurs de l'OCDE. Qualite des soins. Cancer. Paris, Editions de l'OCDE, 2007, 195 p. |
8 | AROME (2011). Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area). Crit Rev Oncol Hematol, 78, 1-16. DOI ScienceOn |
9 | Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. DOI ScienceOn |
10 | Rocconi RP, Estes JM, Leath 3rd CA, et al (2005). Management strategies for stage IB2 cervical cancer: a costeffectiveness analysis. Gynecol Oncol, 97, 387-94. DOI |
11 | Gueddari M (2001). Diagnostic precoce des cancers du sein et du col uterin. Ministere de la Sante, direction de l'epidemiologie et de lutte contre les maladies, Rabat 2001. |
12 | Arveux P, Benard S, Bouee S, et al (2007). Cout de la prise en charge du cancer invasif du col de l'uterus en France. Bull Cancer, 94, 219-24. |
13 | Schaffer P, Bilger P, Allemand H (1994). L'efficacite et le cout du depistage du cancer du col de l'uterus. Rev Med Assurance Maladie, 2, 108-20. |
14 | Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 256-7. DOI |
15 | El M'rini T, Arveux P, Gay C, et al (1997). Estimation du cout du traitement du cancer du col. Rev Epidemiol Sante Publique, 45, 508-15. |
16 | Fahs MC, Mandelblatt J, Schechter C, Muller C (1992). Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med, 117, 520-7. DOI ScienceOn |
17 | Wolstenholme JL, Whynes DK (1998). Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer, 34, 1889-93. DOI |
18 | Zappa M, Cecchini S, Ciatto S, et al (1998). Measurement of the cost of screening for cervical cancer in the district of Florence, Italy. Tumori, 84, 631-5. |
19 | Ferlay J, Shin H, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI |
20 | Goldie SJ, Kim JJ, Myers E (2006). Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine, 24, 164-70. DOI |
21 | International Agency for Research on Cancer (IARC) (2008). World cancer report. |
22 | Holmes J, Hemmett L, Garfield S (2005). The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ, 6, 30-7. |